Clomiphene citrate and Estradiol — Competitive Intelligence Brief

Clomiphene citrate and Estradiol (Clomiphene citrate and Estradiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM) combined with estrogen replacement. Area: Endocrinology / Reproductive Medicine.

marketed Selective estrogen receptor modulator (SERM) combined with estrogen replacement Estrogen receptor alpha and beta Endocrinology / Reproductive Medicine Small molecule

Target snapshot

Clomiphene citrate and Estradiol (Clomiphene citrate and Estradiol) — Maher elesawi kamel elesawi. Clomiphene citrate acts as a selective estrogen receptor modulator to block negative feedback and increase gonadotropin secretion, while estradiol provides exogenous estrogen supplementation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clomiphene citrate and Estradiol TARGET	Clomiphene citrate and Estradiol	Maher elesawi kamel elesawi	marketed	Selective estrogen receptor modulator (SERM) combined with estrogen replacement	Estrogen receptor alpha and beta
Mirabegron with vaginal estrogen cream	Mirabegron with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Beta-3 adrenergic agonist (mirabegron) + topical estrogen (vaginal cream)	Beta-3 adrenergic receptor (mirabegron); estrogen receptor alpha and beta (vaginal estrogen)
Estrogen vaginal cream	Estrogen vaginal cream	The University of Texas Health Science Center, Houston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha and beta
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
Estradiol/norethindrone acetate	Estradiol/norethindrone acetate	Myovant Sciences GmbH	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
teriparatide and raloxifene	teriparatide and raloxifene	Medical University of Vienna	marketed	Combination therapy: PTH analog and selective estrogen receptor modulator (SERM)	PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
Estradiol+MPA	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) combined with estrogen replacement class)

1. Maher elesawi kamel elesawi · 1 drug in this class